Detail akcie Chemomab Sp ADS online

Business Summary: Chemomab Therapeutics Ltd (formerly known as Anchiano Therapeutics Ltd) is a Israel-based clinical-stage biopharmaceutical company. The Company specializes in the development of patient oriented targeted therapy for the treatment of a wide range of fibrotic and inflammatory diseases with high unmet medical need among others. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Chemomab Therapeutics Ltd - ADR revenues was not reported. Net loss decreased 35% to $7.1M. Lower net loss reflects Research and development decrease of 47% to $4.7M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.14 to -$0.05.